VANCOUVER, Washington, May 16, 2024 Dear Shareholders, I write today to provide an update on CytoDyn Inc. , as we approach the end of our 2024 fiscal year , and to sincerely thank you for.
Obituaries: David Walter Martin :: Bay Area Reporter ebar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ebar.com Daily Mail and Mail on Sunday newspapers.
Atlanta (Georgia) [US], August 10 (ANI/PRNewswire): Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve patient health, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 - a small molecule inhibitor of coronavirus main protease (Mpro) - in healthy adult volunteers. The data, presented today at the poster session of the 11th International Conference on Emerging Infectious Diseases (ICEID), showed FB2001 to be safe and well tolerated among trial participants. Adverse events reported during the trial were mostly mild-to-moderate in severity, with no significant differences observed between participants in the Chinese and American study centers. "We are pleased by the positive results from FB2001's phase 1 trial. It is a significant milestone for us and the healthcare community", said Dr CJ Wang, Chief Executive Officer of Frontier Biotechnolog